Lessons learnt from hydroxychloroquine/azithromycin in treatment of COVID-19

doi:10.1183/13993003.02002-2021

Editorial

. 2022 Jan 6;59(1):2102002.

doi: 10.1183/13993003.02002-2021. Print 2022 Jan.

Lessons learnt from hydroxychloroquine/azithromycin in treatment of COVID-19

Jiuyang Xu^{1

2

3}, Bin Cao^{4

3

5}

Affiliations

¹ Tsinghua University School of Medicine, Beijing, China.
² Dept of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, China-Japan Friendship Hospital, National Center for Respiratory Medicine, National Clinical Research Center for Respiratory Diseases, Beijing, China.
³ Institute of Respiratory Medicine, Chinese Academy of Medical Sciences, Beijing, China.
⁴ Dept of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, China-Japan Friendship Hospital, National Center for Respiratory Medicine, National Clinical Research Center for Respiratory Diseases, Beijing, China caobin_ben@163.com.
⁵ Tsinghua University-Peking University Joint Center for Life Sciences, Beijing, China.

PMID: 34326192
PMCID: PMC8340617
DOI: 10.1183/13993003.02002-2021

Editorial

Lessons learnt from hydroxychloroquine/azithromycin in treatment of COVID-19

Jiuyang Xu et al. Eur Respir J. 2022.

. 2022 Jan 6;59(1):2102002.

doi: 10.1183/13993003.02002-2021. Print 2022 Jan.

Authors

Jiuyang Xu^{1

2

3}, Bin Cao^{4

3

5}

Affiliations

¹ Tsinghua University School of Medicine, Beijing, China.
² Dept of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, China-Japan Friendship Hospital, National Center for Respiratory Medicine, National Clinical Research Center for Respiratory Diseases, Beijing, China.
³ Institute of Respiratory Medicine, Chinese Academy of Medical Sciences, Beijing, China.
⁴ Dept of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, China-Japan Friendship Hospital, National Center for Respiratory Medicine, National Clinical Research Center for Respiratory Diseases, Beijing, China caobin_ben@163.com.
⁵ Tsinghua University-Peking University Joint Center for Life Sciences, Beijing, China.

PMID: 34326192
PMCID: PMC8340617
DOI: 10.1183/13993003.02002-2021

Abstract

Solid pre-clinical investigations serve as the basis for clinical research. High quality clinical trials remain the definitive measure to evaluate an interventional therapy. Clinical decisions should be independent from media and political propaganda. https://bit.ly/3iaNBsB

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: J. Xu has nothing to disclose. Conflict of interest: B. Cao has nothing to disclose.

Comment on

Azithromycin and hydroxychloroquine in hospitalised patients with confirmed COVID-19: a randomised double-blinded placebo-controlled trial.
Sivapalan P, Ulrik CS, Lapperre TS, Bojesen RD, Eklöf J, Browatzki A, Wilcke JT, Gottlieb V, Håkansson KEJ, Tidemandsen C, Tupper O, Meteran H, Bergsøe C, Brøndum E, Bødtger U, Bech Rasmussen D, Graff Jensen S, Pedersen L, Jordan A, Priemé H, Søborg C, Steffensen IE, Høgsberg D, Klausen TW, Frydland MS, Lange P, Sverrild A, Ghanizada M, Knop FK, Biering-Sørensen T, Lundgren JD, Jensen JS; ProPAC-COVID writing group on behalf of the ProPAC-COVID Study Group. Sivapalan P, et al. Eur Respir J. 2022 Jan 6;59(1):2100752. doi: 10.1183/13993003.00752-2021. Print 2022 Jan. Eur Respir J. 2022. PMID: 34083403 Free PMC article. Clinical Trial.

Cited by

Learning from the Experience of the COVID-19 Pandemic: A New Paradigm for Occupational Biohazard Assessment and Management.
Durando P, Rahmani A, Montecucco A, Dini G. Durando P, et al. Med Lav. 2023 Dec 7;114(6):e2023056. doi: 10.23749/mdl.v114i6.15452. Med Lav. 2023. PMID: 38060205 Free PMC article.
Clinical presentation and outcomes of chronic dialysis patients with COVID-19: A single center experience from Greece.
Bacharaki D, Karagiannis M, Sardeli A, Giannakopoulos P, Tziolos NR, Zoi V, Piliouras N, Arkoudis NA, Oikonomopoulos N, Tzannis K, Kavatha D, Antoniadou A, Vlahakos D, Lionaki S. Bacharaki D, et al. World J Nephrol. 2022 Mar 25;11(2):58-72. doi: 10.5527/wjn.v11.i2.58. World J Nephrol. 2022. PMID: 35433341 Free PMC article.
A Comprehensive Review of the Clinical Pharmacokinetics, Pharmacodynamics, and Drug Interactions of Nirmatrelvir/Ritonavir.
Gerhart J, Cox DS, Singh RSP, Chan PLS, Rao R, Allen R, Shi H, Masters JC, Damle B. Gerhart J, et al. Clin Pharmacokinet. 2024 Jan;63(1):27-42. doi: 10.1007/s40262-023-01339-y. Epub 2024 Jan 4. Clin Pharmacokinet. 2024. PMID: 38177893 Free PMC article. Review.
Update June 2022: management of hospitalised adults with coronavirus disease 2019 (COVID-19): a European Respiratory Society living guideline.
Roche N, Crichton ML, Goeminne PC, Cao B, Humbert M, Shteinberg M, Antoniou KM, Ulrik CS, Parks H, Wang C, Vandendriessche T, Qu J, Stolz D, Brightling C, Welte T, Aliberti S, Simonds AK, Tonia T, Chalmers JD. Roche N, et al. Eur Respir J. 2022 Aug 10;60(2):2200803. doi: 10.1183/13993003.00803-2022. Print 2022 Aug. Eur Respir J. 2022. PMID: 35710264 Free PMC article.
Factors Associated with Self-Medication during the COVID-19 Pandemic: A Cross-Sectional Study in Pakistan.
Chaudhry B, Azhar S, Jamshed S, Ahmed J, Khan LU, Saeed Z, Madléna M, Gajdács M, Rasheed A. Chaudhry B, et al. Trop Med Infect Dis. 2022 Oct 25;7(11):330. doi: 10.3390/tropicalmed7110330. Trop Med Infect Dis. 2022. PMID: 36355873 Free PMC article.

See all "Cited by" articles

References

1. Ben-Zvi I, Kivity S, Langevitz P, et al. . Hydroxychloroquine: from malaria to autoimmunity. Clin Rev Allergy Immunol 2012; 42: 145–153. doi:10.1007/s12016-010-8243-x - DOI - PMC - PubMed
1. Barnard DL, Day CW, Bailey K, et al. , Evaluation of immunomodulators, interferons and known in vitro SARS-CoV inhibitors for inhibition of SARS-CoV replication in BALB/c mice. Antivir Chem Chemother 2006; 17: 275–284. doi:10.1177/095632020601700505 - DOI - PubMed
1. Keyaerts E, Li S, Vijgen L, et al. . Antiviral activity of chloroquine against human coronavirus OC43 infection in newborn mice. Antimicrob Agents Chemother 2009; 53: 3416–3421. doi:10.1128/AAC.01509-08 - DOI - PMC - PubMed
1. Keyaerts E, Vijgen L, Maes P, et al. . In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine. Biochem Biophys Res Commun 2004; 323: 264–268. doi:10.1016/j.bbrc.2004.08.085 - DOI - PMC - PubMed
1. Niu J, Shen L, Huang B, et al. . Non-invasive bioluminescence imaging of HCoV-OC43 infection and therapy in the central nervous system of live mice. Antiviral Res 2020; 173: 104646. doi:10.1016/j.antiviral.2019.104646 - DOI - PMC - PubMed

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

LinkOut - more resources

Full Text Sources
Other Literature Sources
- The Lens - Patent Citations Database
Miscellaneous
- NCI CPTAC Assay Portal

[1] Ben-Zvi I, Kivity S, Langevitz P, et al. . Hydroxychloroquine: from malaria to autoimmunity. Clin Rev Allergy Immunol 2012; 42: 145–153. doi:10.1007/s12016-010-8243-x - DOI - PMC - PubMed

[2] Ben-Zvi I, Kivity S, Langevitz P, et al. . Hydroxychloroquine: from malaria to autoimmunity. Clin Rev Allergy Immunol 2012; 42: 145–153. doi:10.1007/s12016-010-8243-x - DOI - PMC - PubMed

[3] Barnard DL, Day CW, Bailey K, et al. , Evaluation of immunomodulators, interferons and known in vitro SARS-CoV inhibitors for inhibition of SARS-CoV replication in BALB/c mice. Antivir Chem Chemother 2006; 17: 275–284. doi:10.1177/095632020601700505 - DOI - PubMed

[4] Barnard DL, Day CW, Bailey K, et al. , Evaluation of immunomodulators, interferons and known in vitro SARS-CoV inhibitors for inhibition of SARS-CoV replication in BALB/c mice. Antivir Chem Chemother 2006; 17: 275–284. doi:10.1177/095632020601700505 - DOI - PubMed

[5] Keyaerts E, Li S, Vijgen L, et al. . Antiviral activity of chloroquine against human coronavirus OC43 infection in newborn mice. Antimicrob Agents Chemother 2009; 53: 3416–3421. doi:10.1128/AAC.01509-08 - DOI - PMC - PubMed

[6] Keyaerts E, Li S, Vijgen L, et al. . Antiviral activity of chloroquine against human coronavirus OC43 infection in newborn mice. Antimicrob Agents Chemother 2009; 53: 3416–3421. doi:10.1128/AAC.01509-08 - DOI - PMC - PubMed

[7] Keyaerts E, Vijgen L, Maes P, et al. . In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine. Biochem Biophys Res Commun 2004; 323: 264–268. doi:10.1016/j.bbrc.2004.08.085 - DOI - PMC - PubMed

[8] Keyaerts E, Vijgen L, Maes P, et al. . In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine. Biochem Biophys Res Commun 2004; 323: 264–268. doi:10.1016/j.bbrc.2004.08.085 - DOI - PMC - PubMed

[9] Niu J, Shen L, Huang B, et al. . Non-invasive bioluminescence imaging of HCoV-OC43 infection and therapy in the central nervous system of live mice. Antiviral Res 2020; 173: 104646. doi:10.1016/j.antiviral.2019.104646 - DOI - PMC - PubMed

[10] Niu J, Shen L, Huang B, et al. . Non-invasive bioluminescence imaging of HCoV-OC43 infection and therapy in the central nervous system of live mice. Antiviral Res 2020; 173: 104646. doi:10.1016/j.antiviral.2019.104646 - DOI - PMC - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Lessons learnt from hydroxychloroquine/azithromycin in treatment of COVID-19

Affiliations

Lessons learnt from hydroxychloroquine/azithromycin in treatment of COVID-19

Authors

Affiliations

Abstract

Conflict of interest statement

Comment on

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Other Literature Sources

Miscellaneous

Abstract

Conflict of interest statement

Comment on

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

Related information

LinkOut - more resources

Full Text Sources

Other Literature Sources

Miscellaneous